Logo image of CLNN

CLENE INC (CLNN) Stock Fundamental Analysis

NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD

4.28  -0.09 (-2.06%)

After market: 4.26 -0.02 (-0.47%)

Fundamental Rating

2

Overall CLNN gets a fundamental rating of 2 out of 10. We evaluated CLNN against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of CLNN have multiple concerns. CLNN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLNN had negative earnings in the past year.
In the past year CLNN has reported a negative cash flow from operations.
In the past 5 years CLNN always reported negative net income.
In the past 5 years CLNN always reported negative operating cash flow.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -114.84%, CLNN is doing worse than 80.07% of the companies in the same industry.
Industry RankSector Rank
ROA -114.84%
ROE N/A
ROIC N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

CLNN has a Gross Margin of 78.86%. This is amongst the best in the industry. CLNN outperforms 84.56% of its industry peers.
In the last couple of years the Gross Margin of CLNN has grown nicely.
The Profit Margin and Operating Margin are not available for CLNN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLNN has more shares outstanding than it did 1 year ago.
CLNN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CLNN has a worse debt to assets ratio.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -18.31, we must say that CLNN is in the distress zone and has some risk of bankruptcy.
CLNN's Altman-Z score of -18.31 is on the low side compared to the rest of the industry. CLNN is outperformed by 83.66% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.31
ROIC/WACCN/A
WACC9.27%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

CLNN has a Current Ratio of 1.36. This is a normal value and indicates that CLNN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, CLNN is doing worse than 83.66% of the companies in the same industry.
A Quick Ratio of 1.36 indicates that CLNN should not have too much problems paying its short term obligations.
CLNN's Quick ratio of 1.36 is on the low side compared to the rest of the industry. CLNN is outperformed by 82.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.36
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.02% over the past year.
The Revenue for CLNN has decreased by -43.82% in the past year. This is quite bad
Measured over the past years, CLNN shows a very negative growth in Revenue. The Revenue has been decreasing by -21.98% on average per year.
EPS 1Y (TTM)54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
Revenue 1Y (TTM)-43.82%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%10.96%

3.2 Future

CLNN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.34% yearly.
Based on estimates for the next years, CLNN will show a very strong growth in Revenue. The Revenue will grow by 306.69% on average per year.
EPS Next Y45.7%
EPS Next 2Y32.29%
EPS Next 3Y30.46%
EPS Next 5Y21.34%
Revenue Next Year-41.18%
Revenue Next 2Y246.56%
Revenue Next 3Y544.03%
Revenue Next 5Y306.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLNN. In the last year negative earnings were reported.
Also next year CLNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as CLNN's earnings are expected to grow with 30.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.29%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLENE INC

NASDAQ:CLNN (6/20/2025, 8:25:56 PM)

After market: 4.26 -0.02 (-0.47%)

4.28

-0.09 (-2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners12.32%
Inst Owner Change-6.08%
Ins Owners22.82%
Ins Owner Change-0.01%
Market Cap38.43M
Analysts81.54
Price Target43.86 (924.77%)
Short Float %4.78%
Short Ratio2.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.62%
Min EPS beat(2)-91.95%
Max EPS beat(2)90.71%
EPS beat(4)3
Avg EPS beat(4)9.67%
Min EPS beat(4)-91.95%
Max EPS beat(4)90.71%
EPS beat(8)5
Avg EPS beat(8)-0.74%
EPS beat(12)8
Avg EPS beat(12)14.45%
EPS beat(16)10
Avg EPS beat(16)36.2%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-31.37%
Max Revenue beat(2)39.93%
Revenue beat(4)1
Avg Revenue beat(4)-1.86%
Min Revenue beat(4)-31.37%
Max Revenue beat(4)39.93%
Revenue beat(8)3
Avg Revenue beat(8)9.1%
Revenue beat(12)5
Avg Revenue beat(12)18.17%
Revenue beat(16)8
Avg Revenue beat(16)32.69%
PT rev (1m)0%
PT rev (3m)-14.34%
EPS NQ rev (1m)39.93%
EPS NQ rev (3m)42.28%
EPS NY rev (1m)0%
EPS NY rev (3m)7.55%
Revenue NQ rev (1m)-14.45%
Revenue NQ rev (3m)-47.17%
Revenue NY rev (1m)-13.45%
Revenue NY rev (3m)-24.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 109.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.23
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.14
OCFYN/A
SpS0.04
BVpS-0.55
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.86%
FCFM N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.25%
Cap/Sales 1.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.36
Quick Ratio 1.36
Altman-Z -18.31
F-Score4
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)176.04%
Cap/Depr(5y)141.46%
Cap/Sales(3y)385.66%
Cap/Sales(5y)305.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
EPS Next Y45.7%
EPS Next 2Y32.29%
EPS Next 3Y30.46%
EPS Next 5Y21.34%
Revenue 1Y (TTM)-43.82%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%10.96%
Revenue Next Year-41.18%
Revenue Next 2Y246.56%
Revenue Next 3Y544.03%
Revenue Next 5Y306.69%
EBIT growth 1Y28.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29%
EBIT Next 3Y31.93%
EBIT Next 5Y64.33%
FCF growth 1Y51.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.22%
OCF growth 3YN/A
OCF growth 5YN/A